Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Ainuovirine + lamivudine + tenofovir for CNS symptoms in treatment-experienced adults with HIV-1
ChiCTR2400079814Phase 4Not yet recruiting
- Sponsor
- Chengdu Public Health Clinical Medical Centre
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ainuovirine in human immunodeficiency virus infection (HIV), sponsored by Chengdu Public Health Clinical Medical Centre. Primary endpoint: Change in CNS-related symptoms from baseline. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ainuovirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400079814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079814.